3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1
3
Phase 2/3
1
Phase 1/2
1
Status
Recruiting
3
Withdrawn
1
Unknown
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Tuberous Sclerosis
1
Interventions
Oxaliplatin
5
Leucovorin
5
Fluorouracil
5
Gemcitabine
4
pirarubicin
2
liposomal doxorubicin
2
Surgical Procedures, Operative
2
Radiation
2
Paclitaxel
2
Neoadjuvant Therapy
2
Folfox protocol
2
Capecitabine
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
vocimagene amiretrorepvec
1
taxane
1
sulindac sulfone
1
remdesivir
1
pembrolizumab
1
nimotuzumab
1
methylnaltrexone
1
lenvatinib
1
irinotecan sucrosofate
1
carbon-11 acetate
1
bavituximab
1
alovudine
1
aflibercept
1
Thyroxine
1
Therapeutics
1
Temozolomide
1
Taxes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Withdrawn
×
Everolimus
×
Clear all
NCT02860494
2021-05-03
EVEROST
Hospices Civils de Lyon
Phase 2/3
Withdrawn